Immunotherapy, cancer and rheumatological diseases: A review of the literature and a series of cases in a university hospital

Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 158, 10.1056/NEJMra1703481 Cappelli, 2017, Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systemic review of the literature, Arthritis Care Res (Hoboken), 69, 1751, 10.1002/acr.23177 Calabrese, 2017, Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity, RMD Open, 3, e000412, 10.1136/rmdopen-2016-000412 McCarthy, 2006, The toxins of William B. Coley and the treatment of bone and soft-tissue sarcoma, Iowa Orthop J, 26, 154 Cappelli, 2018, Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen, Semin Arthritis Rheum, 10.1016/j.semarthrit.2018.02.011 Belkhir, 2017, Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment, Ann Rheum Dis, 76, 1747, 10.1136/annrheumdis-2017-211216 Le Burel, 2018, Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy, Ann Rheum Dis, 3, 468, 10.1136/annrheumdis-2016-210820 Puzanov, 2017, Managing toxicities associated with immune checkpoints inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J Immunother Cancer, 5, 95, 10.1186/s40425-017-0300-z Naidoo, 2017, Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade, Oncologist, 22, 627, 10.1634/theoncologist.2016-0390 Horvat, 2015, Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol, 33, 3193, 10.1200/JCO.2015.60.8448 Calzascia, 2007, TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice, J Clin Invest, 117, 3833 Esfahani, 2017, Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade, N Engl J Med, 376, 1989, 10.1056/NEJMc1703047